One Pharmacy / Article
Compounding and Compliance: Building a Safe, Compliant HRT Program in Your Clinic
Compounding and Compliance: Building a Safe, Compliant HRT Program in Your Clinic
Hormone replacement therapy (HRT) programs require more than thoughtful prescribing. Clinic leaders also need a reliable process for selecting compounded medications, documenting medical necessity, managing patient-specific prescriptions, and verifying the pharmacy behind the program.
In 2026, the distinction between traditional compounding pharmacies and FDA-registered outsourcing facilities remains especially important. A pharmacy partner should do more than fill prescriptions. The right partner should help your clinic understand the applicable rules, build a consistent workflow, and support safe communication between prescribers, pharmacists, and patients.
This guide covers the core compliance considerations for functional medicine clinics, HRT practices, and primary care organizations.
Start with the clinical need for compounding
Compounding may be appropriate when an FDA-approved medication does not meet an individual patient’s needs. Examples may include:
- A dosage strength that is not commercially available
- A different dosage form or route of administration
- An excipient or dye that a patient cannot tolerate
- A formulation that supports an established clinical plan
- A patient-specific combination that cannot be obtained as an approved product
Compounded medication should not be treated as a routine substitute simply because it is preferred by a clinic or patient. The prescriber should evaluate whether an approved product meets the patient’s needs and document why a compounded preparation is medically appropriate when one is used.
That documentation belongs in the patient’s medical record and should be reflected clearly in the prescription or supporting communication with the pharmacy. A practical record may include the patient’s diagnosis or treatment goal, relevant history, prior intolerance or allergy, the reason a commercial product is unsuitable, and the intended dosage form and strength.
The pharmacy cannot replace the prescriber’s clinical judgment. However, a consultative pharmacy partner can help identify missing information before the prescription reaches production.
503A vs. 503B: Why the distinction matters
The FDA’s overview of sections 503A and 503B is an important reference for clinic leaders.
503A traditional compounding pharmacies
A 503A pharmacy generally compounds for an identified individual patient based on a valid patient-specific prescription. Limited anticipatory compounding may be permitted when it is based on a history of valid prescriptions and an established relationship, but the final product still requires a valid prescription before distribution.
For clinics, the operational takeaway is simple: a 503A pharmacy generally should not be used as a source of non-patient-specific office stock. Prescriptions should identify the patient and contain enough information for the pharmacy to prepare and dispense the medication appropriately.
State pharmacy laws may add requirements, so your workflow should be reviewed for every state in which your clinic prescribes, dispenses, administers, or ships medication.
503B outsourcing facilities
A 503B outsourcing facility may compound without patient-specific prescriptions and may supply certain compounded products as office stock. These facilities are registered with the FDA and must comply with current good manufacturing practice, or cGMP, requirements.
That does not mean every 503B facility can produce every HRT formulation or that every product may be held as office stock. The facility must meet applicable federal and state requirements, use permitted ingredients, follow product restrictions, and comply with registration, reporting, labeling, and distribution rules.
Ask a potential pharmacy partner to explain, in writing:
- Whether it operates as a 503A pharmacy, a 503B outsourcing facility, or both
- Which entity will compound and dispense the product
- Whether the product is patient-specific or office stock
- What licenses and registrations apply to the product and destination state
- Whether controlled-substance rules apply
- Who is responsible for labeling, storage, administration, and follow-up
Do not rely on a marketing label such as “503B quality.” Verify the facility’s actual status and the specific product pathway.
Build clinical justification into your HRT workflow
A compliant HRT process should make documentation easy for prescribers and consistent for pharmacy staff.
At the point of prescribing, consider including:
The patient-specific reason for compounding
Explain why the approved product or commercially available strength does not meet the patient’s needs.The exact formulation requested
Include active ingredients, concentration, dosage form, route, directions, quantity, and beyond-use or refill information as appropriate.Relevant patient factors
Document allergies, sensitivities, prior treatment response, swallowing difficulties, absorption concerns, or other facts that influenced the decision.Monitoring and follow-up plan
Identify the clinical monitoring needed for the patient’s therapy, including follow-up visits, laboratory evaluation, adverse-effect monitoring, or dose adjustments.Communication with the pharmacy
Use a defined process for clarifying prescriptions. Verbal changes, substitutions, and formulation adjustments should be documented according to applicable law and clinic policy.
Clinical justification should be individualized. A general statement such as “patient requests compounded HRT” may not adequately explain why compounding is necessary.
Clinics should also avoid presenting compounded HRT as automatically safer, more effective, or equivalent to an FDA-approved product. FDA states that compounded drugs are not reviewed for safety, effectiveness, or quality before marketing in the same way as approved drugs. Patient counseling should be accurate and balanced.
Understand USP <795>, <797>, and <800>
The applicable USP chapter depends on the preparation and how it is handled.
- USP <795> addresses nonsterile compounding, including many capsules, creams, gels, and other preparations.
- USP <797> addresses sterile compounding, including sterile injectables and other preparations administered through sterile routes.
- USP <800> addresses handling of hazardous drugs to protect patients, workers, and the environment.
A hormone preparation is not automatically subject to every chapter. The pharmacy should determine which standards apply based on the product, ingredients, route, and handling process.
For sterile HRT products, ask about cleanroom controls, personnel competency, environmental monitoring, media-fill testing, end-product testing, storage, and beyond-use dating. For nonsterile preparations, ask about master formulation records, ingredient verification, process controls, stability support, and quality checks.
If a hormone or ingredient is classified as hazardous, the clinic should also understand its own responsibilities for receiving, storing, administering, handling spills, using personal protective equipment, and disposing of waste. A pharmacy partner should help define the handoff between pharmacy and clinic responsibilities.
Treat PCAB accreditation as one part of due diligence
PCAB accreditation, administered through the Accreditation Commission for Health Care, can be a meaningful quality signal. PCAB standards are designed around USP requirements for sterile and nonsterile compounding and include areas such as personnel training, facilities, equipment, standard operating procedures, quality assurance, documentation, and performance improvement.
Accreditation is not a substitute for licensure, FDA registration, state compliance, or your own review. It also does not mean that every prescription or batch is automatically risk-free.
When reviewing accreditation, confirm:
- The accreditation is current
- The accredited location matches the location preparing your medication
- The scope includes the type of compounding your clinic needs
- The pharmacy can provide evidence of ongoing quality and corrective-action processes
- The accreditation is not being confused with FDA approval of a compounded drug
A pharmacy that is transparent about its accreditation, licenses, inspection history, and quality systems is easier for a clinic to evaluate.
Ask for testing and lot-specific documentation
A certificate of analysis (COA) is not an FDA approval of a compounded medication. However, appropriate documentation can help demonstrate ingredient and product quality.
For active pharmaceutical ingredients, ask whether the pharmacy receives and evaluates batch-specific COAs from qualified manufacturers or laboratories. Depending on the product, relevant information may include identity, potency, purity, impurities, residual solvents, and other specifications.
For sterile preparations, ask about the pharmacy’s finished-product testing program. Depending on the formulation and risk, this may include potency, identity, sterility, endotoxin, or other testing. The pharmacy should be able to explain which tests are performed, how often, by whom, and how failed or out-of-specification results are handled.
You should also understand how the pharmacy:
- Tracks lot numbers and expiration or beyond-use dates
- Manages complaints and adverse events
- Conducts recalls
- Investigates temperature excursions
- Communicates product quality concerns to prescribers
- Maintains records for audits and patient follow-up
A practical pharmacy-partner checklist
Before referring patients or building a high-volume HRT program, clinic leaders should verify the pharmacy partner’s:
- Legal entity and operating model
- State licenses and shipping permissions
- 503A or 503B status, as applicable
- PCAB accreditation status and scope, if applicable
- USP <795>, <797>, and <800> procedures
- Ingredient sourcing and COA review process
- Third-party testing program
- Prescription intake and clarification workflow
- Patient counseling and refill process
- Adverse-event and recall procedures
- Turnaround times and escalation contacts
- Packaging, shipping, storage, and temperature-control practices
- Ability to support the clinic as volume grows
This review should be repeated periodically, not completed only once during onboarding.
Work with a pharmacy partner that supports your process
A safe HRT program depends on coordination. The pharmacy should understand your clinical model, patient population, prescribing workflow, follow-up expectations, and documentation needs.
One Pharmacy takes a consultative approach to compounding partnerships. Our team can work with functional medicine clinics, HRT practices, and primary care organizations to clarify prescription requirements, discuss formulation needs, support documentation workflows, and help your team establish a more reliable process for patient care.
Contact One Pharmacy to discuss your clinic’s HRT program, pharmacy workflow, and compounding needs.
This article is for general educational purposes and is not legal advice or a substitute for clinical judgment. Requirements may vary by state, product, dosage form, route, and pharmacy structure. Clinics should consult qualified regulatory and legal professionals regarding their specific operations.